Duane Mitchell, MD, Ph.D., University of Florida professor of neurosurgery and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy and his team will join Immunomic Therapeutics, Inc., a company pioneering the study of nucleic acid immunotherapy, to present new clinical data at the 2019 Society for Neurology (SNO) Annual Meeting in Phoenix.
Dr. Mitchell and the team will discuss results from a Phase II clinical trial known as (ATTAC-II) evaluating the efficacy of autologous CMV pp65-LAMP RNA pulsed dendritic cell vaccines mixed with GM-CSF and administered during cycles of adjuvant dose-intensified temozolomide. The study, sponsored by the University of Florida, demonstrated that a CMV pp65-LAMP RNA-pulsed DC vaccination was associated with profound immunologic and clinical response in a patient with MGMT unmethylated midline glioblastoma.
The Research Centers
University of Florida’s Duane Mitchell was the study chair, and the principal investigators were Nicholas Avgeropoulos, MD, and Maryam Rahman, MD. Duke University was also involved with Katherine Peters, MD, Ph.D. as principal investigator for that institutions.
Chief Scientific Officer Dr. Teri Heiland noted: “The new clinical data to be presented demonstrates the power of our UNITE technology platform and validates our therapeutic approach utilizing vaccines to treat difficult cancers like glioblastoma.”
Immunomic has been around since 2005 and has raised at least $14.1 million, according to CrunchBase. They have sought to make it easier for patients to participate in their clinical trials establishing a travel fund in 2017. Their pipeline is mostly preclinical, but they also have a number of investigational therapies licensed to Astellas. Their DC-based pp65-CMV has made it to Phase III.
Duane Mitchell, Study Chair
Maryam Rahman, MD
Call to Action: Interested in learning more? See the links for the abstracts for the University of Florida.